Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.

Sebastiano Buti Alessandro Olivari Cristina MasiniDavide BimbattiDonata SartoriPaola ErmacoraCarlo CattriniMaria Giuseppa VitaleErnesto RossiClaudia MucciariniMimma RizzoMichele SisaniMatteo SantoniGiandomenico RovielloVeronica MollicaVincenza ConteducaFrancesco GrilloneMarika CinauseroGiuseppe PratiFrancesco AtzoriMarco StellatoFrancesco MassariMelissa Bersanelli

Published in: Therapeutic advances in urology (2024)

Our findings suggest a clinically relevant effectiveness of lenvatinib plus everolimus combination with an acceptable toxicity profile for heavily pretreated patients with mRCC.

Keyphrases

renal cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
systematic review
oxidative stress
patient reported outcomes